Anzeige
Mehr »
Login
Donnerstag, 31.10.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0N95A | ISIN: LT0000128092 | Ticker-Symbol: YG4
Frankfurt
31.10.24
08:05 Uhr
1,195 Euro
0,000
0,00 %
1-Jahres-Chart
AKOLA GROUP AB Chart 1 Jahr
5-Tage-Chart
AKOLA GROUP AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,1301,38020:29
GlobeNewswire (Europe)
221 Leser
Artikel bewerten:
(1)

AB "Akola Group": Resolutions of the Annual General Meeting of Shareholders of AB Akola Group

The Annual General Meeting (hereinafter - the Meeting) of AB Akola Group (hereinafter - the Company) was held on 31 October 2024.

On the day the Meeting is convened the total number of the Company's shares is 167,170,481, and the number of shares granting voting rights is 166,508,509. The own shares in the amount of 661,972 acquired by the Company do not grant voting rights.

In total 25 Company's shareholders, who owned shares of the Company at the end of the Accounting day of the Meeting (24 October 2024), participated in the Meeting having 138,965,128 share votes, which amounted to 83.46 percent of the total number of the Company's share votes. 22 duly filled General Voting Ballots were presented before the Meeting.

The Board member and CFO of the Company Mažvydas Šileika, deputizing Company's CEO, participated in the Meeting.

The quorum existed.

Decisions of the Meeting:

1.Presentation of the Company's Audit Committee Activity Report.

Presented. No voting.

2.Presentation of the independent auditor's report.

Presented. No voting.

3.Presentation of the Consolidated Annual Report of the Company for the financial year 2023/2024.

Presented. No voting.

4.Approval of the Company's Remuneration Report.

Approve the Company's Remuneration Report.

Results of voting:
FOR - 138,965,128 votes (including 138,885,287 share votes of shareholders who voted in advance).
AGAINST - 0.
DID NOT VOTE - 0

5.Approval of the consolidated and the Company's set of financial statements for the financial year ended 30 June, 2024.

Approve the consolidated and the Company's set of financial statements for the financial year ended 30 June, 2024.

Results of voting:
FOR - 138,965,128 votes (including 138,885,287 share votes of shareholders who voted in advance).
AGAINST - 0.
DID NOT VOTE - 0

6.Approval of the Distribution of the Company's Profit/Loss.

Approve the Distribution of the Company's Profit/Loss:

1)Retained earnings - profit (loss) of the previous financial year at the end of the accounting financial yearEUR 46,543,950
2)Net profit (loss) of the financial yearEUR 75 920 296
3)The profit (loss) of the accounting financial year not recognized in the profit (loss) account-
4)The transfers from the reserves-
5)The shareholder's contributions to cover the losses of the Company (if shareholders decided to cover all or part of losses)-
6)The total profit (loss) available for appropriationEUR 122,464,246
7)The part of the profit allocated to the legal reserveEUR 3,796,015
8)The part of the profit allocated to the reserve of the own share acquisition-
9)The part of the profit allocated to the reserve of shares issue-
10)The part of the profit allocated to the other reserves-
11)The part of the profit allocated for the payment of dividendsEUR 4,995,255*
12)The part of the profit allocated for payment of annual bonuses to the Board, employees and other purposes-
13)Retained earnings - profit at the end of the financial year carried forward to the next financial yearEUR 113,672,976

* Dividends in amount of EUR 4,995,255 are allocated for the financial year ended on 30 June, 2024, which consist EUR 0.03 with taxes per one share of the Company (calculated without own shares acquired by the Company).

Results of voting:
FOR - 138,965,128 votes (including 138,885,287 share votes of shareholders who voted in advance).
AGAINST - 0.
DID NOT VOTE - 0

7.Approval of a new wording of Rules for Granting Shares of the Company.

Approve a new wording of the Company's Rules for Granting Shares.

Results of voting:
FOR - 138,965,128 votes (including 138,885,287 share votes of shareholders who voted in advance).
AGAINST - 0.
DID NOT VOTE - 0

8.Approval of a new wording of the Articles of Association of the Company.

8.1. Approve a new wording of the Articles of Association of the Company, the provisions of the Articles of Association of the Company comply with the amended provisions of the Law on Companies of the Republic of Lithuania, as well as reducing the number of members of the Company's Board from 6 to 5 members.
8.2. Authorize (including the power to delegate) the Chief Executive Officer of the Company to sign the new wording of the Articles of Association of the Company and to register them with the Register of Legal Entities pursuant to the procedure under law.

Results of voting:
FOR - 138,965,128 votes (including 138,885,287 share votes of shareholders who voted in advance).
AGAINST - 0.
DID NOT VOTE - 0


9.Determination of the remuneration of the members of the Company's Audit Committee.

9.1. Grant an additional one-off remuneration of EUR 600 (six hundred euros) to each existing member of the Audit Committee for the increased workload of the Audit Committee in the financial year 2023/2024.
9.2. Set the annual remuneration to each member of the Audit Committee, payable from 2025 onwards, as follows: EUR 1,600 (one thousand six hundred euros) to the Chairman of the Audit Committee, and EUR 1,200 (one thousand two hundred euros) to the Audit Committee member.
9.3. Determine that the annual remuneration to the members of the Audit Committee shall be paid within one month after the Annual General Meeting of Shareholders of the Company.

Results of voting:
FOR - 138,965,128 votes (including 138,885,287 share votes of shareholders who voted in advance).
AGAINST - 0.
DID NOT VOTE - 0

Contact for further information:

Mažvydas Šileika, CFO of AB Akola Group

Mob. +370 619 19 403

E-mail m.sileika@akolagroup.lt (mailto:m.sileika@akolagroup.lt)

Attachments

  • Audit Committee Report (https://ml-eu.globenewswire.com/Resource/Download/84ab6ef2-3688-4e7e-b8cd-ca63374e67a0)
  • Independent Auditor's Report (https://ml-eu.globenewswire.com/Resource/Download/e2d31793-d93f-41b0-93a1-357a3e390c8e)
  • Set of audited annual reports in ESEF format (Financial Statements, Annual Report with Sustainability Report and annexes - Governance Code Compliance Report and Remuneration Report) (https://ml-eu.globenewswire.com/Resource/Download/6767ae4a-bd67-48ec-a23d-53c41b7f2038)
  • Articles of Association of the Company (https://ml-eu.globenewswire.com/Resource/Download/2b734fc3-544b-4ed9-99d5-ddff90e36085)
  • The Rules for Granting Shares (https://ml-eu.globenewswire.com/Resource/Download/152d52e6-af7b-4776-bcaf-0fb36ca1d555)

© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.